

IRONWOOD PHARMACEUTICALS INC  
Form 8-K  
March 09, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**Current Report Pursuant to**  
**Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported):

**March 3, 2011**

**IRONWOOD PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State of incorporation  
or organization)

**001-34620**  
(Commission file number)

**04-3404176**  
(I.R.S. Employer  
Identification Number)

**301 Binney Street**  
**Cambridge, Massachusetts**  
(Address of principal  
executive offices)

**02142**  
(Zip code)

**(617) 621-7722**

Registrant's telephone number.

Edgar Filing: IRONWOOD PHARMACEUTICALS INC - Form 8-K

including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 4.02. Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.**

(a) On March 3, 2011, the audit committee of Ironwood Pharmaceuticals, Inc. (the "Company"), after discussion with the Company's management and the Company's independent registered public accounting firm, approved management's decision to reclassify an approximate \$2.9 million income tax benefit associated with the sale of the Company's subsidiary, Microbia, Inc., in the quarterly period ended September 30, 2010. This reclassification had no effect on the Company's cash position, nor did it have any effect on the Company's net loss or net loss per share for the quarterly period ended September 30, 2010 or for the year ended December 31, 2010.

In the unaudited condensed consolidated statements of operations in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2010, the Company recognized all of the aforementioned income tax benefit in net income (loss) from discontinued operations. Based on the Company's reevaluation of the relevant accounting guidance, the Company has now reclassified this amount as income tax benefit related to continuing operations for the quarterly period ended September 30, 2010, which is offset by an identical and corresponding income tax provision in net income (loss) from discontinued operations for the same period.

The Company will discuss the reclassification in further detail in Note 23, *Restatement and Selected Quarterly Financial Data (Unaudited)* to its consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2010, which the Company expects to file with the Securities and Exchange Commission on or before March 31, 2011.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Ironwood Pharmaceuticals, Inc.**

Dated: March 9, 2011

By: /s/ Michael J. Higgins  
Name: Michael J. Higgins  
Title: Chief Operating Officer and Chief  
Financial Officer